Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis
Childhood Obesity · 2025
DOI: 10.1089/chi.2025.0007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Childhood Obesity, 2025. Verfasst von Courtney E Batt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Academic Pediatrics and Adolescent Medicine, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, …. Hauptthemen laut MEDLINE: Topiramate, Phentermine, Pediatric Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Background
National guidelines support adjunct anti-obesity medications to treat adolescent obesity. The combination of phentermine and topiramate is accessible and efficacious in controlled trials, but very little clinic-based data exist. We sought to describe prescribing characteristics, effectiveness, and safety of phentermine and/or topiramate in a clinical setting.
Methods
A retrospective chart review was conducted among patients prescribed phentermine and/or topiramate for obesity in a pediatric obesity management program between 2019 and 2021. Patient and provider characteristics, percent BMI change, vital signs, laboratory tests, and discontinuation data were assessed.
Results
Patients ( n = 126) with mean age of 15.5 years, 50% Hispanic, 66% with public insurance, were included, of whom 83% had severe obesity and 51% had ≥3 comorbidities. Discontinuation at 12 months was observed in 58% of the sample, driven primarily by loss to follow-up. Patients who continued medication had significant BMI reductions at 3 (−3.1%), 6 (−4.7%), 9 (−5.2%), and 12 (−7.5%) months. Heart rate increased on phentermine by 5–10 beats per minute at 9 and 12 months only. Adverse effects were experienced by 25.8% at 3 months and most commonly included mood changes, fatigue, and paresthesias. Side effects and side effect-related discontinuation were most common with topiramate monotherapy.
Conclusions
Phentermine and/or topiramate resulted in BMI reduction in most patients exposed for 3–12 months. Safety data support individualized monitoring of heart rate and neuropsychiatric side effects. High attrition and variables associated with differential BMI response require further study. Most patients had severe, complicated obesity at medication initiation and may benefit from earlier intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Academic Pediatrics and Adolescent Medicine, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.
- Department of Pediatrics, Children's Hospital Colorado, University of Colorado, Aurora, Colorado, USA.
- Department of Pediatrics, Section of Endocrinology, Children's Hospital Colorado, University of Colorado, Aurora, Colorado, USA.
- Department of Pediatrics, Section of Nutrition, Children's Hospital Colorado, University of Colorado, Aurora, Colorado, USA.
ORCID-Profile: Courtney E Batt, Megan M Kelsey
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Batt, C. E., Puccio, O. C., Kelsey, M. M., Boles, R. E., & Moore, J. M. (2025). Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis. Childhood Obesity. https://doi.org/10.1089/chi.2025.0007
Vancouver
Batt CE, Puccio OC, Kelsey MM, Boles RE, Moore JM. Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis. Childhood Obesity. 2025. doi:10.1089/chi.2025.0007
BibTeX
@article{Batt2025,
author = {Batt, Courtney E and Puccio, Olivia C and Kelsey, Megan M and Boles, Richard E and Moore, Jaime M},
title = {Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis},
journal = {Childhood Obesity},
year = {2025},
doi = {10.1089/chi.2025.0007}
}
EUVIMED